| Primary |
| Drug Use For Unknown Indication |
27.3% |
| Antiplatelet Therapy |
14.3% |
| Hypertension |
10.5% |
| Thrombosis Prophylaxis |
9.6% |
| Angina Pectoris |
7.4% |
| Product Used For Unknown Indication |
4.1% |
| Cerebrovascular Accident Prophylaxis |
3.3% |
| Coronary Arterial Stent Insertion |
3.3% |
| Myocardial Infarction |
3.0% |
| Acute Myocardial Infarction |
2.8% |
| Cerebral Infarction |
2.5% |
| Cardiac Failure |
1.7% |
| Prophylaxis |
1.7% |
| Coronary Artery Disease |
1.4% |
| Hyperlipidaemia |
1.4% |
| Transient Ischaemic Attack |
1.4% |
| Acute Coronary Syndrome |
1.1% |
| Anticoagulant Therapy |
1.1% |
| Arrhythmia |
1.1% |
| Diabetes Mellitus |
1.1% |
|
| Death |
10.1% |
| Pyrexia |
10.1% |
| Thrombosis In Device |
9.0% |
| Hepatotoxicity |
5.6% |
| Thrombotic Microangiopathy |
5.6% |
| Toxic Epidermal Necrolysis |
5.6% |
| Interstitial Lung Disease |
4.5% |
| Liver Disorder |
4.5% |
| Organising Pneumonia |
4.5% |
| Sepsis |
4.5% |
| Thrombocytopenia |
4.5% |
| Thrombotic Thrombocytopenic Purpura |
4.5% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.4% |
| Hepatitis Cholestatic |
3.4% |
| Myocardial Infarction |
3.4% |
| Neuroborreliosis |
3.4% |
| Neutropenia |
3.4% |
| Pulmonary Alveolar Haemorrhage |
3.4% |
| Rash Generalised |
3.4% |
| Renal Failure |
3.4% |
|
| Secondary |
| Hypertension |
11.9% |
| Thrombosis Prophylaxis |
11.6% |
| Drug Use For Unknown Indication |
10.8% |
| Angina Pectoris |
9.4% |
| Antiplatelet Therapy |
8.4% |
| Product Used For Unknown Indication |
4.7% |
| Coronary Arterial Stent Insertion |
4.4% |
| Acute Myocardial Infarction |
4.3% |
| Ill-defined Disorder |
4.2% |
| Diabetes Mellitus |
4.1% |
| Myocardial Infarction |
4.0% |
| Cerebral Infarction |
3.0% |
| Hyperlipidaemia |
3.0% |
| Stent Placement |
2.9% |
| Percutaneous Coronary Intervention |
2.6% |
| Gastric Ulcer |
2.4% |
| Prophylaxis |
2.2% |
| Angina Unstable |
2.0% |
| Hypercholesterolaemia |
2.0% |
| Pyrexia |
2.0% |
|
| Thrombosis In Device |
8.3% |
| Liver Disorder |
7.4% |
| Interstitial Lung Disease |
6.5% |
| Platelet Count Decreased |
6.5% |
| Pulmonary Alveolar Haemorrhage |
6.5% |
| Shock |
6.5% |
| Toxic Epidermal Necrolysis |
6.5% |
| Myocardial Infarction |
5.6% |
| Retroperitoneal Haematoma |
5.6% |
| Sepsis |
4.6% |
| Thrombosis |
4.6% |
| Cardiac Tamponade |
3.7% |
| Hepatic Function Abnormal |
3.7% |
| Rash |
3.7% |
| Respiratory Failure |
3.7% |
| Shock Haemorrhagic |
3.7% |
| Vasodilatation |
3.7% |
| White Blood Cell Count Decreased |
3.7% |
| Acute Generalised Exanthematous Pustulosis |
2.8% |
| Agranulocytosis |
2.8% |
|
| Concomitant |
| Hypertension |
24.5% |
| Product Used For Unknown Indication |
15.1% |
| Drug Use For Unknown Indication |
13.8% |
| Angina Pectoris |
5.6% |
| Diabetes Mellitus |
5.5% |
| Rheumatoid Arthritis |
4.5% |
| Acute Myocardial Infarction |
3.6% |
| Cerebral Infarction |
3.4% |
| Cardiac Failure |
2.8% |
| Hypercholesterolaemia |
2.6% |
| Prophylaxis |
2.5% |
| Insomnia |
2.2% |
| Constipation |
2.1% |
| Gastritis |
1.9% |
| Multiple Myeloma |
1.9% |
| Cardiovascular Disorder |
1.9% |
| Type 2 Diabetes Mellitus |
1.8% |
| Hyperphosphataemia |
1.5% |
| Hyperlipidaemia |
1.4% |
| Atrial Fibrillation |
1.4% |
|
| Rhabdomyolysis |
11.0% |
| Interstitial Lung Disease |
10.5% |
| Vomiting |
9.5% |
| Renal Impairment |
5.5% |
| White Blood Cell Count Increased |
5.5% |
| Cardiac Failure |
4.5% |
| Cerebral Infarction |
4.5% |
| Coronary Artery Stenosis |
4.5% |
| Pneumonia |
4.5% |
| Pruritus |
4.5% |
| Pyrexia |
4.5% |
| Renal Failure |
4.0% |
| Acute Myocardial Infarction |
3.5% |
| Hypoglycaemia |
3.5% |
| Somnolence |
3.5% |
| Syncope |
3.5% |
| Thrombocytopenia |
3.5% |
| Weight Decreased |
3.5% |
| Blood Pressure Decreased |
3.0% |
| Cardio-respiratory Arrest |
3.0% |
|
| Interacting |
| Drug Use For Unknown Indication |
50.0% |
| Atrial Fibrillation |
20.8% |
| Coronary Artery Disease |
16.7% |
| Cerebrovascular Accident |
8.3% |
| Carotid Arteriosclerosis |
4.2% |
|
| Vomiting |
50.0% |
| Peptic Ulcer Haemorrhage |
25.0% |
| Subdural Haematoma |
25.0% |
|
